According to a new study by co-authors McGowan Institute for Regenerative Medicine
affiliated faculty members Mary Amanda Dew, Ph.D. (pictured top), professor of psychiatry, psychology, epidemiology, and biostatistics at the University of Pittsburgh and also the director of the Clinical Epidemiology Program at the Western Psychiatric Institute and Clinic, and Joan C. Rogers, Ph.D. (pictured bottom), professor and chair of the Department of Occupational Therapy within the University of Pittsburgh School of Health and Rehabilitation Sciences and also professor of psychiatry and a professor within the School of Nursing, and other colleagues from the University of Pittsburgh School of Medicine, donepezil--a medication used to treat dementia in Alzheimer’s patients--was found to enhance language, memory, and executive functioning in older, depressed adults to a greater extent than was evident from the use of an antidepressant medication alone. The study, published in the Archives of General Psychiatry, is the first to provide scientifically rigorous evidence to guide clinical practice in older adults with both major depression and mild cognitive impairment.
“Cognitive impairment is a core feature of depression in older adults and may foreshadow the development of dementia,” said Charles F. Reynolds III, M.D., lead author of the study and UPMC Endowed Chair of Geriatric Psychiatry. “While treatment of depression usually benefits associated cognitive impairment, it does not completely regulate cognitive impairment and may not delay the progression to dementia. So, even in remission, older adults with past depression may still show residual cognitive difficulties, such as slowing of information processing speed and impairments in executive or language function. Our study showed that by adding donepezil, cognition can be improved beyond that which is seen simply with the treatment of depression itself.”
For the study, researchers compared 130 depressed adults over the age of 65 – with 67 receiving donepezil, marketed under the trade name Aricept, and 63 receiving a placebo. The participants were followed for 2 years while researchers explored the effects of donepezil and placebo on 5 areas of neuropsychological functioning, including speed of information processing, memory, language, visuospatial functioning, and executive functioning, or brain processes that are responsible for planning and abstract thinking.
The researchers noted two unexpected findings: donepezil seemed to delay the progression of mild cognitive impairment to frank dementia, and the use of the drug was associated with somewhat higher recurrence rates of clinical depression episodes, said Dr. Reynolds. “So, there was both a benefit and a risk to adding donepezil to antidepressant pharmacotherapy in older adults. Fortunately, the majority of recurrent depressive episodes could be treated to remission.”
Adding donepezil to maintenance antidepressant medication appears to be useful to the care of older, depressed patients with mild cognitive impairment but does not benefit those with normal cognition. The researchers stress that clinicians should watch for early signs of any depressive relapse and treat as needed.
Illustration: McGowan Institute for Regenerative Medicine.
University of Pittsburgh Schools of the Health Sciences Media Relations Press Release (01/03/11)
Annals of Long-term Care.com (01/17/11)
Bio: Dr. Mary Amanda Dew
Bio: Dr. Joan C. Rogers
Abstract (Archives of General Psychiatry, 2011 Jan;68(1):51-60.)